[go: up one dir, main page]

MA42902A - Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car) - Google Patents

Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)

Info

Publication number
MA42902A
MA42902A MA42902A MA42902A MA42902A MA 42902 A MA42902 A MA 42902A MA 42902 A MA42902 A MA 42902A MA 42902 A MA42902 A MA 42902A MA 42902 A MA42902 A MA 42902A
Authority
MA
Morocco
Prior art keywords
lymphocytes
antigen receptor
mil
car
marinal
Prior art date
Application number
MA42902A
Other languages
English (en)
Inventor
Ivan M Borrello
Susan Lee
Kimberly A Noonan
Drew M Pardoll
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of MA42902A publication Critical patent/MA42902A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4275—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Dans certains modes de réalisation, des lymphocytes infiltrant la moelle («mil») comprenant un récepteur d'antigène chimère («car») sont fournis. Dans certains aspects, les modes de réalisation concernent un procédé de fabrication d'un mil recombinant, comprenant l'obtention d'une moelle osseuse comprenant des mils; et transfectant, transformant ou transduisant les mil avec un acide nucléique codant pour un récepteur d'antigène chimère. Dans certains aspects, les modes de réalisation concernent une méthode de traitement d'une condition chez un sujet, comprenant l'administration au sujet d'un mil comprenant un car.
MA42902A 2015-07-08 Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car) MA42902A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562189928P 2015-07-08 2015-07-08

Publications (1)

Publication Number Publication Date
MA42902A true MA42902A (fr) 2018-05-16

Family

ID=57686063

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42902A MA42902A (fr) 2015-07-08 Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)

Country Status (12)

Country Link
US (3) US11478548B2 (fr)
EP (1) EP3320087A4 (fr)
JP (2) JP2018518978A (fr)
KR (1) KR20180039068A (fr)
CN (1) CN108026510A (fr)
AU (1) AU2016291199B2 (fr)
CA (1) CA2990694A1 (fr)
HK (2) HK1255208A1 (fr)
IL (1) IL256434B2 (fr)
MA (1) MA42902A (fr)
MX (1) MX2017017083A (fr)
WO (1) WO2017008019A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42902A (fr) * 2015-07-08 2018-05-16 Univ Johns Hopkins Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
TW201904578A (zh) * 2017-05-10 2019-02-01 美商艾歐凡斯生物治療公司 源自液體腫瘤之腫瘤浸潤性淋巴細胞的擴增和該經擴增腫瘤浸潤性淋巴細胞之治療用途
EP3714041A1 (fr) * 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion de lymphocytes de sang périphérique (pbl) à partir de sang périphérique
JP7558563B2 (ja) 2018-03-15 2024-10-01 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
MX2020006131A (es) * 2018-03-22 2020-08-17 Windmil Therapeutics Inc Linfocitos infiltrantes de medula especificos para cancer de prostata y usos de los mismos.
US20210244760A1 (en) * 2018-06-12 2021-08-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptor tumor infiltrating lymphocytes
JPWO2020004337A1 (ja) * 2018-06-27 2021-08-02 国立大学法人東海国立大学機構 Ｃｄ３７特異的キメラ抗原レセプター
KR20210031898A (ko) * 2018-07-13 2021-03-23 난징 레전드 바이오테크 씨오., 엘티디. 전염병을 치료하기 위한 공동수용체 시스템
CN113166227A (zh) * 2018-11-05 2021-07-23 温德弥尔治疗公司 克隆性增加的骨髓浸润淋巴细胞及其用途
CN113396215A (zh) * 2018-11-30 2021-09-14 温德弥尔治疗公司 表达嵌合抗原受体(car)的骨髓浸润淋巴细胞(mil)、其制造方法及在疗法中使用的方法
US20220168350A1 (en) * 2019-03-22 2022-06-02 Windmil Therapeutics, Inc. Lung Cancer Specific Marrow Infiltrating Lymphocytes and Uses Thereof
BR112022011795A2 (pt) 2019-12-20 2022-08-30 Instil Bio Uk Ltd Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
US20230100744A1 (en) * 2020-02-28 2023-03-30 Windmil Therapeutics, Inc. Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils
WO2022066872A1 (fr) * 2020-09-24 2022-03-31 Windmil Therapeutics, Inc. Lymphocytes infiltrant la moelle (mil) exprimant des récepteurs de lymphocytes t, procédés de fabrication de ceux-ci et procédé d'utilisation en thérapie
WO2022076606A1 (fr) * 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Traitement de patients souffrant de cpnpc avec des thérapies de lymphocytes infiltrant les tumeurs
EP4225330A1 (fr) * 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Traitement de patients souffrant de cpnpc avec des thérapies de lymphocytes infiltrant les tumeurs
WO2022098985A1 (fr) * 2020-11-05 2022-05-12 Windmil Therapeutics, Inc. Lymphocytes infiltrant la moelle spécifique d'un glioblastome et utilisations associées

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2364152A4 (fr) * 2008-11-03 2013-02-13 Univ Johns Hopkins Procédés pour la préparation et l utilisation de lymphocytes infiltrant la moelle (mils)
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013063419A2 (fr) * 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania Récepteur immunitaire chimérique spécifique complètement humain, anti-mésothéline pour un ciblage redirigé de cellules exprimant la mésothéline
WO2013109759A1 (fr) * 2012-01-17 2013-07-25 Northeastern University Méthodes et compositions de développement in vitro de lymphocytes t régulateurs immunosuppresseurs et utilisations de celles-ci
MX2015000426A (es) * 2012-07-13 2015-07-14 Univ Pennsylvania Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico.
DK2925329T3 (da) * 2012-11-27 2021-03-22 Ivan Marques Borrello Anvendelse af cyclophosphamid-behandlede knoglemarvsinfiltrerende lymfocytter efter transplantationer til øgning af antitumorimmunitet
HUE046961T2 (hu) * 2013-02-20 2020-04-28 Univ Pennsylvania Rák kezelése humanizált EGFRVIII elleni kiméra antigénreceptor alkalmazásával
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP2017504601A (ja) 2013-12-20 2017-02-09 セレクティスＣｅｌｌｅｃｔｉｓ 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法
PT3188740T (pt) * 2014-09-04 2021-06-23 Univ Johns Hopkins Ativação de linfócitos infiltrantes de medula em condições hipóxicas em alternância com normóxicas
WO2017004150A1 (fr) 2015-06-29 2017-01-05 The Johns Hopkins University Thérapie faisant intervenir des récepteurs antigéniques chimériques de point de contrôle immunitaire
MA42902A (fr) 2015-07-08 2018-05-16 Univ Johns Hopkins Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)

Also Published As

Publication number Publication date
WO2017008019A1 (fr) 2017-01-12
JP2018518978A (ja) 2018-07-19
US20230016031A1 (en) 2023-01-19
AU2016291199B2 (en) 2022-12-22
US11478548B2 (en) 2022-10-25
US20230210990A1 (en) 2023-07-06
KR20180039068A (ko) 2018-04-17
HK1254313A1 (zh) 2019-07-19
CN108026510A (zh) 2018-05-11
AU2016291199A1 (en) 2018-02-15
MX2017017083A (es) 2018-05-23
JP2021121230A (ja) 2021-08-26
EP3320087A4 (fr) 2019-01-23
IL256434A (en) 2018-02-28
EP3320087A1 (fr) 2018-05-16
IL256434B2 (en) 2025-02-01
CA2990694A1 (fr) 2017-01-12
US20180200367A1 (en) 2018-07-19
IL256434B1 (en) 2024-10-01
HK1255208A1 (zh) 2019-08-09

Similar Documents

Publication Publication Date Title
MA42902A (fr) Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)
BR112022009679A2 (pt) Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos
ZA202109042B (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonists
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
HRP20241258T1 (hr) Interleukin-2/interleukin-2 receptor alfa fuzijski proteini i postupci upotrebe
MX2019004810A (es) Ácidos ribonucleicos mensajeros para aumentar respuestas inmunes y métodos para usarlos.
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
SG10201907399RA (en) Enhanced delivery of viral particles to the striatum and cortex
EP4599847A3 (fr) Protéines de spicule de coronavirus de préfusion et leur utilisation
MA39390A1 (fr) Thérapie génique pour le traitement de la rétinite pigmentaire
MX392069B (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
MX2020010035A (es) Receptores de celulas t anti-papilomavirus 16 e7 humano.
EA201890355A1 (ru) Новые способы индукции иммунного ответа
PE20170771A1 (es) Composiciones y metodos de uso para tratar trastornos metabolicos
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
PE20191614A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo
MX2023009421A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2015016304A (es) Proteinas de union al antigeno del receptor de oncostatina m.
MX2021003146A (es) Anticuerpos anti-ifnar1 para tratar enfermedades autoinmunitarias.
MX2021006399A (es) Linfocitos infiltrantes de medula osea (mils) que expresan receptores de antigenos quimericos (car), metodo de fabricacion de los mismos y metodo de uso en terapia.
BR112017012928A2 (pt) uso de um ectonucleotídeo pirofosfatase fosfodiesterase (npp1); uso de uma composição farmacêutica; e uso de um snpp1 humano recombinante isolado, fragmento ou proteína de fusão deste
MY193519A (en) Method for decreasing immunogenicity of protein and peptide
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.